12 results on '"Adwaita Gore"'
Search Results
2. Expert survey on management of prostate cancer in India: Real-world insights into practice patterns
- Author
-
Ganesh, Bakshi, Hemant, Tongaonkar, Sanjai, Addla, Santosh, Menon, Aditya, Pradhan, Abhay, Kumar, Abhijit, Bapat, Adwaita, Gore, Amit, Joshi, Anand, Raja, Anil, Bradoo, Anita, Ramesh, Anup, Kumar, Archi, Agrawal, Asawari, Ambekar, Ashish, Joshi, Ashish, Singh, Bhupendra Pal, Singh, Deepak, Dabkara, Dhiraj, Khadakban, Gagan, Gautam, Gagan, Prakash, Harvinder Singh, Pahwa, Hemant Kumar, Goel, Jagdeesh, Kulkarni, Jeeban Jyoti, Mishra, Kaushal, Patel, Mahendra, Pal, Percy Jal, Chibber, Priya, Tiwari, Radheshyam, Naik, S K, Raghunath, Rahul, Krishnatry, Rajendra, Shimpi, Rakesh, Sharma, Rakesh, Taran, Sameer, Trivedi, Sanjay, Nabar, Sanjoy, Surekha, Satish, Kumar, Satyakam Krishna, Sawaimoon, Shailesh, Raina, Srivatsa, Narasimha, Suresh, Advani, Syed Mohammed, Ghouse, Vamshi Krishna, Muddu, Vashishth, Maniar, Vivek, Venkat, and Vedang, Murthy
- Subjects
Male ,Oncology ,Surveys and Questionnaires ,Humans ,India ,Prostatic Neoplasms ,Practice Patterns, Physicians' - Abstract
To gain insights on the diverse practice patterns and treatment pathways for prostate cancer (PC) in India, the Urological Cancer Foundation convened the first Indian survey to discuss all aspects of PC, with the objective of guiding clinicians on optimizing management in PC. A modified Delphi method was used, wherein a multidisciplinary panel of oncologists treating PC across India developed a questionnaire related to screening, diagnosis and management of early, locally advanced and metastatic PC and participated in a web-based survey (WBS) (n = 62). An expert committee meeting (CM) (n = 48, subset from WBS) reviewed the ambiguous questions for better comprehension and reanalyzed the evidence to establish a revote for specific questions. The threshold for strong agreement and agreement was ≥90% and ≥75% agreement, respectively. Sixty-two questions were answered in the WBS; in the CM 31 questions were revoted and 4 questions were added. The panelists selected answers based on their best opinion and closest to their practice strategy, not considering financial constraints and access challenges. Of the 66 questions, strong agreement was reached for 17 questions and agreement was achieved for 22 questions. There were heterogeneous responses for 27 questions indicative of variegated management approaches. This is one of the first Indian survey, documenting the diverse clinical practice patterns in the management of PC in India. It aims to provide guidance in the face of technological advances, resource constraints and sparse high-level evidence.
- Published
- 2022
- Full Text
- View/download PDF
3. Treatment of advanced non-small-cell lung cancer: First line, maintenance, and second line– Indian consensus statement update(Under the aegis of Lung Cancer Consortium Asia, Indian Cooperative Oncology Network, Indian Society of Medical and Pediatric Oncology, Molecular Oncology Society, and Association of Physicians of India)
- Author
-
Narayanankutty Warrier, Vijay Patil, Adwaita Gore, Govind Babu, Shekhar Patil, Nirmal Vivek Raut, Kumar Prabhash, Nitesh Rohatgi, Amish Vora, Bharat Bhosale, Shailesh Arjun Bondarde, Vanita Noronha, T. P. Sahoo, Sewanti Limaye, Bharat Vaswani, and Ullas Batra
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,General Medicine ,medicine.disease ,Lorlatinib ,Targeted therapy ,Ramucirumab ,Clinical trial ,Pemetrexed ,Maintenance therapy ,Docetaxel ,Internal medicine ,medicine ,business ,Lung cancer ,medicine.drug - Abstract
The management of patients with advanced non-small-cell lung cancer (NSCLC) is becoming increasingly complex, with the identification of driver mutations/rearrangements and the development and availability of appropriate targeted therapies. In 2018, a group of medical oncologists with expertise in treating lung cancers used data from the published literature and experience to arrive at practical consensus recommendations for the treatment of advanced NSCLC for use by the community oncologists. These recommendations were subsequently published in 2019, with a plan to be updated annually. This article is an update to the 2019 consensus statement. For updating the consensus statement, a total of 25 clinically relevant questions on the management of patients with NSCLC on which consensus would be sought were drafted. The PubMed database was searched using the following terms combined with the Boolean operator “AND:” (lung cancer, phase 3, non-small cell lung cancer AND non-small-cell lung cancer [MeSH Terms]) AND (clinical trial, phase 3 [MeSH Terms]) AND (clinical trial, phase iii [MeSH Terms]). In addition, “carcinoma, non-smallcell lung/drug therapy” (MeSH Terms), “lung neoplasms/drug therapy” (MeSH), clinical trial, phase III (MeSH Terms) were used to refine the search. The survey results and literature were reviewed by the core members to draft the consensus statements. The expert consensus was that molecular testing is a crucial step to be considered for patients with NSCLC at baseline, and in those who progress on first-line chemotherapy and have not undergone any prior testing. For mutations/rearrangement-negative patients who progress on first-line immunotherapy, doublet or single-agent chemotherapy with docetaxel and/or gemcitabine and/or ramucirumab should be considered. Patients who progress on the newer anaplastic lymphoma kinase inhibitors should be considered for second-line therapy with lorlatinib or systemic chemotherapy. Maintenance therapy with pemetrexed is preferred for NSCLC with non-squamous histology and should be avoided in NSCLC with squamous histology.
- Published
- 2021
- Full Text
- View/download PDF
4. Pegfilgrastim: More Cost Effective and Equally Efficacious Option as Compared to Filgrastim in Autologous Stem Cell Transplant
- Author
-
Vipul Sheth, Tapan Saikia, Adwaita Gore, R. Jain, and Amit Ghanekar
- Subjects
medicine.medical_specialty ,Chemotherapy ,Hematology ,business.industry ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Neutropenia ,Filgrastim ,medicine.disease ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Autologous stem-cell transplantation ,Internal medicine ,PEG ratio ,medicine ,Original Article ,business ,Febrile neutropenia ,Pegfilgrastim ,030215 immunology ,medicine.drug - Abstract
Use of growth factor after high-dose chemotherapy (HDC) and autologous peripheral blood stem cell (PBSC) support is current standard in reducing days of neutropenia. This retrospective study aims to compare the efficacy of two standard growth factors, pegfilgrastim (PEG) and filgrastim (FIL) after HDC. We collected data on 195 consecutive adult patients who received an autotransplant (myeloma, lymphoma and others) between January 2004 and December 2014 at two tertiary care centres. The primary end point was the duration of neutropenia in terms of days to reach an ANC > 0.5 × 10(9)/L. Filgrastim was given to 110 patients and PEG was given to 85 patients. Time to engraftment, defined as the time to reach an ANC of 0.5 × 10(9)/L on 2 consecutive days after the day of auto-SCT, was 12.6 days with FIL compared with 12.1 days with PEG group (p = 0.126). When comparing the total days of severe neutropenia (WBC
- Published
- 2018
5. LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy
- Author
-
Ravi Thippeswamy, Sadhana Kannan, Reetu Jain, Reena Nair, Navin Khattry, Tapan Saikia, Alok Gupta, Adwaita Gore, and Nandish Jeevangi
- Subjects
Adult ,Male ,Melphalan ,medicine.medical_specialty ,Transplantation Conditioning ,Adolescent ,Platelet Engraftment ,Cyclophosphamide ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Gastroenterology ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Lomustine ,Internal medicine ,medicine ,Mucositis ,Humans ,Multicenter Studies as Topic ,Autografts ,Child ,Etoposide ,Retrospective Studies ,business.industry ,Lymphoma, Non-Hodgkin ,Cytarabine ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,medicine.disease ,Carmustine ,Hodgkin Disease ,Survival Rate ,Child, Preschool ,030220 oncology & carcinogenesis ,Immunology ,Female ,business ,030215 immunology ,medicine.drug - Abstract
We compared the lomustine, cytarabine, cyclophosphamide and etoposide (LACE) and BCNU, etoposide, cytarabine, melphalan (BEAM) conditioning regimens for toxicity, engraftment kinetics, and efficacy in 139 patients undergoing autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma. Ninety-two patients with Hodgkin lymphoma and 47 with non-Hodgkin lymphoma were enrolled. Seventy-five patients received LACE while 64 received BEAM. The incidence of grade 3-4 oral mucositis (9 vs 38%; P < 0.001) and parenteral nutrition requirement (32 vs 69%; P < 0.001) were significantly lower in the LACE cohort. The median days to myeloid (10 vs 11; P = 0.007) and platelet engraftment (13 vs 15; P = 0.026) were shorter for the LACE cohort. Transplant-related mortality in the LACE group was 9% compared to 13% in patients treated with BEAM (P = NS). The probability of overall survival (OS) and progression-free survival (PFS) at 5 years for entire cohort was 46 and 41%, respectively. Probability of OS (LACE 46% vs BEAM 47%; P = NS) and PFS (LACE 37% vs BEAM 47%; P = NS) at 5 years was comparable between two groups. We conclude that LACE has better toxicity profile compared to BEAM and results in similar long-term survival in primary refractory or relapsed lymphoma transplant.
- Published
- 2016
- Full Text
- View/download PDF
6. Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors
- Author
-
S Rajappa, A Pathak, and Adwaita Gore
- Subjects
0301 basic medicine ,Carcinogenesis ,medicine.disease_cause ,03 medical and health sciences ,T790M ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,Epidermal growth factor receptor ,Molecular Targeted Therapy ,Protein Kinase Inhibitors ,Mutation ,biology ,business.industry ,Point mutation ,Protein-Tyrosine Kinases ,Phenotype ,respiratory tract diseases ,Review article ,ErbB Receptors ,030104 developmental biology ,Oncology ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,Non small cell ,Signal transduction ,business - Abstract
Nonsmall cell lung cancer (NSCLC) is increasingly being treated with targeted therapies. Epidermal growth factor receptor (EGFR) has been extensively studied in NSCLC as an oncogenic driver. However, the efficacy of the EGFR tyrosine kinase inhibitors (TKIs) is adversely impacted by the development of resistance. The occurrence of de novo resistance to EGFR TKIs is attributed to multiple mechanisms such as point mutations of oncogenes and chromosomal rearrangements. The development of acquired resistance to EGFR TKIs is facilitated by secondary mutations, phenotypical transformation, aberrance of downstream pathways, and activation of alternate signaling pathways. The T790M mutation is the most common mutation that accounts for about half of the acquired resistance to EGFR TKIs. This review article provides an overview of the common oncogenic drivers, targeted therapies for NSCLC, and the established mechanisms implicated in the development of resistance to the EGFR TKIs.
- Published
- 2018
7. Engraftment Syndrome: Clinical Features and Predictive Factors in Autologous Stem Cell Transplant
- Author
-
Reetu Jain, Amit Ghanekar, Adwaita Gore, Vipul Sheth, and Tapan Saikia
- Subjects
Chemotherapy ,medicine.medical_specialty ,Hematology ,business.industry ,medicine.medical_treatment ,Incidence (epidemiology) ,Engraftment Syndrome ,medicine.disease ,Lymphoma ,03 medical and health sciences ,0302 clinical medicine ,Autologous stem-cell transplantation ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Original Article ,Complication ,business ,030215 immunology ,Pneumonitis - Abstract
Engraftment Syndrome (ES) maybe observed in patients who undergo autologous stem cell transplant (SCT). To investigate clinical criteria for ES diagnosis and analyse the risk factors for this complication, we reviewed all auto-SCT cases (Lymphoma and Myeloma) performed during the past 9 years at two tertiary care centres. We analysed all patients with a non-infectious fever, developed within 7 days of engraftment (first day of ANC of 500 on two consecutive days) in 178 patients undergoing autologous stem cell transplant. A total of 46/178 (25.8%) patients developed non-infectious fever and one or more clinical signs of ES within 7 days of engraftment. In all, 29 (61%) fulfilled the Maiolino and 12 (26%) the Spitzer criteria. The incidence of engraftment syndrome using the Maiolino criteria in our study was 29 (15%), which compares well with Spanish study (13% using same criteria) and the original Maiolino study (20%). All patients with ES satisfactorily recovered and discharged with a median of 20 days from hospital. There was no significant difference in number of days of hospitalisation and days of antibiotics between the ES and non ES arms. All patients recovered without any morbidity and only 1 (2%) patient required readmission for fungal pneumonitis. 8 (17%) patients required ICU admission due to delay in initiation of steroids. None of the factors including number of chemotherapy cycles, conditioning regime, disease status, CD34 collection, growth factors and day of WBC engraftment except female (p = 0.064) were statistically significant (in univariate or multivariate analysis). Our study shows that engraftment syndrome is common in autologous transplant setting. Maiolino criteria to diagnose ES is more sensitive in our setting. If detected and treated early there is not much morbidity or mortality related to ES.
- Published
- 2017
8. Chemoradiation for Laryngeal Cancer: Present Scenario
- Author
-
Dhabhar Bn, Pushkal Dwiwedi, Tapan K. Saikia, and Adwaita Gore
- Subjects
Larynx ,Chemotherapy ,medicine.medical_specialty ,Pathology ,Cetuximab ,business.industry ,medicine.medical_treatment ,Head and neck cancer ,Cancer ,medicine.disease ,Radiation therapy ,Clinical trial ,medicine.anatomical_structure ,Otorhinolaryngology ,Multidisciplinary approach ,medicine ,Intensive care medicine ,business ,medicine.drug - Abstract
The management of locally advanced squamous cell carcinoma of the larynx is complex. Data from recent clinical trials have refined the use of existing therapies, such as radiation therapy and chemotherapy, and providing new treatment options, such as cetuximab. Selecting the most appropriate treatment for an individual patient requires a multidisciplinary approach and careful assessment of the relative advantages and disadvantages of each treatment approach. Chemoradiation is more effective than conventional radiation therapy, but also more toxic. Cetuximab plus radiation therapy is more effective than radiation alone and does not substantially increase radiation-related toxicity. Multimodality approach for laryngeal cancer has shown better organ preservation rates and survival. Ideally, multidisciplinary teams should weigh all these factors when making individual treatment decisions. Data from current trials will help further optimize multimodality treatment for Laryngeal Cancer.
- Published
- 2010
- Full Text
- View/download PDF
9. Efficacy of plerixafor with GCSF for mobilization of PBSC: A single center experience
- Author
-
Amit Ghanekar, Tapan Saikia, Reetu Jain, Vipul Sheth, and Adwaita Gore
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Mobilization ,business.industry ,Plerixafor ,medicine.disease ,Single Center ,Lymphoma ,Haematopoiesis ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Autologous transplantation ,In patient ,Stem cell ,business ,medicine.drug - Abstract
e18011 Background: The combination of plerixafor & GCSF is approved for mobilization of hematopoietic stem cells for autologous transplantation in patients with lymphoma & myeloma whose cells who m...
- Published
- 2015
- Full Text
- View/download PDF
10. The Etiology of Pleural Effusions Develping During Dasatinib Therapy in CML Could Be Variable: Need for Awareness and Investigations
- Author
-
Reetu Jain, Sumaiya Matwankar, Adwaita Gore, Priyadarshini Patil, Tapan Saikia, and Boman Dhabhar
- Subjects
medicine.medical_specialty ,Vincristine ,business.industry ,Pleural effusion ,Immunology ,Imatinib ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Gastroenterology ,Surgery ,Dasatinib ,Imatinib mesylate ,Effusion ,Prednisone ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Adverse effect ,business ,medicine.drug - Abstract
Abstract 4456 Dasatinib is a highly effective oral TKI for CML at various stages of the disease. The most common non-hematologic side-effect is pleural effusion. The exact mechanism of this pathology remains to be fully elicited, although studies report it to be an immunological phenomenon. Current literature shows dasatinib alone to be the cause of such effusions. More recently, pulmonary hypertensions have been reported on dasatinib therapy. However, in our cohort of CML patients receiving dasatinib as a first or second line therapy, other pathologies were documented. Grade 2/3 unilateral pleural effusions were detected in 3 patients. Case 1. A 31 yr old male with CML-CP was on first line dasatinib 100 mg OD and CCyR was documented at 3 months. At 6 month, he was detected to have grade 1/2 bilateral pleural effusion and was managed with drug interruption and oral dexamethasone with no significant reduction of fluid. CBC was normal. Dasatinib was continued. At one year, he lost cytognetic response with emergence of complex karyotype and medullary lymphoid blast crisis was confirmed. Pleural fluid showed lymphoblasts proven by cytology and immunophenotype. He received vincristine and prednisone followed by a change to imatinib. His disease progressed further and died at 2 years from diagnosis. Case 2. A 39 yr old male with molecular relapse and M244V Abl Kd mutation at 8 years since diagnosis and 6.5 yrs on imatinib 400–800 mg daily was offered dasatinib 100 mg OD. After 24 months, he developed grade2 left pleural effusion which responded poorly to drug interruption, therapeutic tapping and prednisone. A few months later he developed constitutional symptoms and CT chest, bronchoscopy/BAL proved to have left lung tuberculosis. Currently, he is responding favorably to anti-tubercular therapy. He was switched back to imatinib and remains in cytogenetic remission. Case 3. A 21 yr old male with cytogenetic non-responder to imatinib 800 mg daily was put on dasatinib 100 mg OD. An MMR was achieved. He developed left pleural effusion after 4 years of dasatinib. Extensive investigation for any specific pathology was not productive. He was put on empiric anti-tubercular therapy with no response. It is being treated as a dasatinib induced effusion. Conclusions. During dasatinib therapy, the causes of pleural effusions could be varied – drug related, extramedullary blast crisis or tubercular. Radiological, cytological and microbiological investigations could be indicated after careful clinical evaluation. Disclosures: Saikia: Bristol -Myers Squibb: Research Funding, Speakers Bureau.
- Published
- 2012
- Full Text
- View/download PDF
11. Comparison of Toxicity and Outcomes of BCNU-Containing Conditioning Regimens Vs LACE in Lymphoma Transplants: A Retrospective Multicenter Analysis
- Author
-
Nandish Jeevangi, Sadhana Kannan, Bharat Bhosale, Tapan Saikia, Amit Joshi, Navin Khattry, Adwaita Gore, Reena Nair, Reetu Jain, and Ravi Thippeswamy
- Subjects
Chemotherapy ,medicine.medical_specialty ,Neutrophil Engraftment ,Platelet Engraftment ,business.industry ,medicine.medical_treatment ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Chemotherapy regimen ,Gastroenterology ,Surgery ,Regimen ,Internal medicine ,Mucositis ,Medicine ,business ,Survival analysis ,Etoposide ,medicine.drug - Abstract
Abstract 2023 Introduction: BCNU – containing regimens (CBV and BEAM) are commonly used in lymphoma transplants. LACE (lomustine-200 mg/ m2 × 1d, etoposide 1000mg/ m2 x1d, ara-c 2000 mg/m2x 2d and cyclophosphamide 1800mg/ m2 for 3d) is an effective and well tolerated regimen reported by few centers. We retrospectively compared the two types of conditioning regimens for toxicity, efficacy and outcome. Methods: One hundred and fifty five patients Hodgkin's disease (HD) and Non Hodgkin's lymphoma (NHL) with primary refractory or relapsed disease from August 1994- May 2011 were included in this study from 3 transplant centers in Mumbai, India. Seventy-nine patients received BEAM or CBV and 76 LACE. One-hundred two patients had HD (BEAM/CBV-50, LACE-52) while 52 had NHL (BEAM/CBV-28, LACE- 24).Stem cell source was peripheral blood (PBSC) in all but one patient in LACE group and 68 patients in BEAM/CBV group. Oral mucositis was graded by WHO criteria while all other toxicities by common toxicity criteria version-3. Total Parenteral Nutrition (TPN) was used in patients with poor oral intake. Neutrophil engraftment (NE) was defined as first day of ANC > 0.5 × 109/L and platelet engraftment (PE) as first of seven days of unsupported platelet count > 20 × 109/L. Sinusoidal Obstruction Syndrome (SOS) of the liver was recorded according to Seattle criteria. Categorical data was analyzed using chi-square while continuous data with Mann Whitney Test. Overall survival (OS) and progression-free survival (PFS) was analyzed using Kaplan Meier survival analysis. Results: The median age at transplant was comparable (BEAM/CBV-25 year, LACE-23 year). Eleven patients in BEAM/CBV group had chemotherapy refractory disease compared to 6 in LACE at the time of transplant (P=0.106).The median serum albumin level (BEAM/CBV -3.9 gm/dl, LACE- 3.9 gm/dl) at the time of diagnosis were comparable. Incidence of grade 3 and 4 oral mucositis was higher in BEAM/CBV compared to LACE group (45 % vs 10%; P Conclusion: In our retrospective multicenter analysis LACE is a better tolerated regimen with lesser toxicity, earlier engraftment and comparable survival rates. Randomized trials comparing it with BCNU- containing regimens are needed. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2011
- Full Text
- View/download PDF
12. Epithelial growth factor receptor (EGFR) expression in squamous cell cancer of buccal mucosa: Incidence and correlation with tumor characteristics in Indian population
- Author
-
Adwaita Gore, Tapan Saikia, P. Dwivedi, and Boman Dhabhar
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Squamous cell cancer ,business.industry ,Incidence (epidemiology) ,Head and neck cancer ,Indian population ,medicine.disease ,medicine.disease_cause ,Buccal mucosa ,Correlation ,Oncology ,Growth factor receptor ,medicine ,Cancer research ,Carcinogenesis ,business - Abstract
e16021 Background: A key motivation for investigating head and neck cancer in India is to understand molecular pathways in carcinogenesis and find indicators of patient survival or markers to selec...
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.